A Case of Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis

Fumiaki Kudo 1, Yasutaka Watanabe 1,2, Yuki Iwai 1, Chihiro Miwa 1, Yoshiaki Nagai 1,5, Hiromitsu Ota 1, Hiroki Yabe 1, Toshio Demitsu 1, Koichi Hagiwara 1,5, Nobuyuki Koyama 2 and Shinichiro Koyama 1

Abstract:
We herein report a 42-year-old man with advanced lung adenocarcinoma and nivolumab-associated dermatomyositis. Nivolumab, an anticancer drug that is classified as an immune checkpoint inhibitor, often induces immune-related adverse events (irAEs). However, there have so far been no reports regarding nivolumab-associated dermatomyositis. This patient was diagnosed with dermatomyositis due to the presence of proximal muscle weakness with abnormal electromyography and magnetic resonance imaging findings; skin lesions, such as heliotrope rash, shawl sign, and periungual erythema; and an elevated serum aldolase level after nivolumab administration. It is important to consider drug-associated dermatomyositis in the differential diagnosis of patients presenting with skin lesions and muscle weakness after nivolumab treatment.

Key words: nivolumab, dermatomyositis, lung cancer, immune-related adverse event

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.9381-17)

Introduction

Nivolumab is a human IgG4 monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor and is classified as an immune checkpoint inhibitor. Borghaei et al. recently reported the results of a phase III study (Checkmate 057 clinical trial), in which nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m² every 3 weeks) was administered to patients with advanced nonsquamous non-small-cell lung cancer, who had previously received platinum-based chemotherapy. The results of this study demonstrated that overall survival was longer for patients who received nivolumab than for those who received docetaxel (1). Therefore, nivolumab treatment has become a standard treatment for patients with lung cancer, and the frequency of administering nivolumab treatments is therefore rapidly increasing. However, this drug has the potential to cause immune-related adverse events (irAEs), such as skin, gastrointestinal, hepatic, and endocrine pathologies. To our knowledge, this is the first report of a patient with lung adenocarcinoma who was treated with nivolumab and whose condition fulfilled all the diagnostic criteria for dermatomyositis as an irAE (2).

Case Report

A 42-year-old male, who had a history of smoking one cigarette pack per day for 20 years, was diagnosed with right lung adenocarcinoma with malignant pleural effusion (cT2aN0M1a stage IV) 2 years and 3 months before starting nivolumab therapy. No EGFR mutations and the ALK fusion oncogene were detected in this patient, who received first-line chemotherapy that consisted of 4 cycles of cisplatin, pemetrexed, and bevacizumab followed by 7 cycles of maintenance therapy with pemetrexed and bevacizumab, and 4 cy-

1Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan, 2Department of Rheumatology, Jichi Medical University, Saitama Medical Center, Japan, 3Department of Dermatology, Jichi Medical University, Saitama Medical Center, Japan, 4Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Japan and 5Department of Pulmonary Medicine, Jichi Medical University, Japan
Received: April 20, 2017; Accepted: December 17, 2017; Advance Publication by J-STAGE: March 9, 2018
Correspondence to Dr. Yasutaka Watanabe, yasuyasu@tokyo-med.ac.jp
of docetaxel as second-line chemotherapy. Upon treatment completion, liver and adrenal metastases, in addition to cervical, axillary, mediastinum, and para-aortic lymph node metastases, were detected, and nivolumab (3 mg/kg, bi-weekly) was initiated as third-line chemotherapy.

The patient experienced general fatigue and minor proximal limb muscle weakness, without demonstrating any abnormal laboratory data or physical symptoms upon examination, a few days after initial nivolumab administration. Grade 1 skin redness, according to Common Terminology Criteria for Adverse Events, appeared on the patient’s left lower leg one week after administration. Nivolumab treatment was therefore discontinued after a total of three courses over one month, due to the appearance of clear proximal muscle weakness six weeks after the initial administration. The patient presented with skin lesions that increased in size and spread all over his face, left ears, back, and hip within two months of the initial administration, and he also demonstrated heliotrope rash, shawl sign, and periungual erythema, which are consistent with the symptoms of cutaneous dermatomyositis (Fig. 1a, b and c). After ceasing nivolumab treatment, the skin lesions partially and gradually resolved. Magnetic resonance imaging (MRI) of the patient’s legs revealed abnormally high intensity areas in the bilateral adductor and obturator muscles during short tau inversion recovery images (Fig. 2a), and an electromyogram revealed typical myogenic conversion (Fig. 2b). On the other hand, the patient’s muscle weakness worsened to the point that squatting was not possible, and the patient was hospitalized for 3 months after the initial nivolumab administration.

Physical examination of the patient upon admission revealed cervical and axillary lymph node enlargement, and

Figure 1. Dermatological findings at 1.5 months after nivolumab treatment show heliotrope eruption (a), shawl sign (b), and periungual erythema (c). Dermatological findings before steroid therapy at 1 month after nivolumab discontinuation show partial scabbing with an improvement of the symptoms (d, e).

Figure 2. a: Magnetic resonance imaging of skeletal muscles reveal abnormal hyper intensity areas (arrows), b: Electromyography of biceps brachii (A), deltoid (B), and external carpi radialis (C, D), all of which display low amplitudes.
newly occurring leg paralysis, and general sensory disorder. Based on the neurological findings, including steroid therapy. We suspected the presence of a spinal and urination disorder appeared two weeks after steroid therapy. After admission, we began to electromyogram results (2). After admission, we began to muscle weakness in extremities, elevated serum aldolase levels, and aldolase elevated to 23.7 IU. Anti-Jo-1 and anti-ARS antibodies were negative. A chest X-ray scan showed right pleural effusion, multiple mediastinal and hilar lymph node swelling, and multiple adrenal bodies were negative. A chest X-ray scan showed right pleural effusion, multiple mediastinal and hilar lymph node swelling, and multiple adrenal metastases.

The condition of the patient fulfilled definite diagnostic criteria for dermatomyositis, based on the Bohan and Peter criteria, and the presence of typical skin lesions, proximal muscle weakness in extremities, elevated serum aldolase levels, muscle pain upon grasping, and abnormal MRI and electromyogram results (2). After admission, we began to administer prednisolone (0.6 mg/kg daily) treatment and the patient’s symptoms slightly and temporarily improved. However, progressive muscle weakness, new back pain, and lower leg numbness were encountered one week after steroid therapy, and a urination disorder appeared two weeks after steroid therapy. We suspected the presence of a spinal cord disorder, based on the neurological findings, including newly occurring leg paralysis, and general sensory disorder.

**Skin lesions with partial scabbing** (Fig. 1d and e). The patient’s muscle strength was slightly weakened at grade 4, according to the score of Manual Muscle Testing (MMT) of the biceps, triceps, iliopsoas, quadriceps, hamstrings, anterior tibialis, and gastrocnemius without laterality, and the patient also complained of muscle pain when grasping with his limbs. Laboratory data (Table) revealed CK levels of 137 mU/mL, while WBC was 11,960 μL, CRP 0.65 mg/dL, and aldolase elevated to 23.7 IU. Anti-Jo-1 and anti-ARS antibodies were negative. A chest X-ray scan showed right pleural effusion, multiple mediastinal and hilar lymph node swelling, and multiple adrenal and liver metastases.

We report a patient with advanced lung adenocarcinoma who developed dermatomyositis as an irAE after nivolumab treatment.

It has been reported that the D-1 inhibitor-related dermatologic characteristics consist of erythematous macules, papules, and plaques that predominantly localize to the trunk and extremities (3). In this case, the initial eruption presented only as lower leg erythema, but progressive dermatologic findings revealed skin lesions typical of dermatomyositis. To our knowledge, this is the first report discussing nivolumab-associated dermatomyositis though there is a case report of a patient with melanoma who presented with drug-associated dermatomyositis as an irAE after ipilimumab treatment which targets a cytotoxic T-lymphocyte antigen (4).

**Table. Laboratory Data at the Time of Diagnosis of Dermatomyositis.**

| CBC          | Serology          |
|--------------|-------------------|
| WBC          | CRP               |
| 11,960 /μL   | 0.65 mg/dL        |
| Neu          | RF                |
| 74 %         | 10 IU/L           |
| Lym          | ANA               |
| 10 %         | 1.80              |
| Mono         | Anti-ARS-Ab       |
| 6 %          | (-)               |
| RBC          | Anti-Jo1-Ab       |
| 426×10⁴ /μL  | (-)               |
| Hb           | Anti-RNP-Ab       |
| 13.2 g/dL    | (-)               |
| Ht           | Anti-SSA-Ab       |
| 40.3 %       | (-)               |
| Pt           | Anti-SSB-Ab       |
| 51.2×10⁴ /μL | (-)               |
| Chemistry    | KL-6              |
| HbA1c        | 256 U/mL          |
| 6.0 %        | TSH               |
| 4.772 μIU/mL | 3.722 mg/dL       |
| TP           | F-T3              |
| 5.4 g/dL     | 1.03 μg/dL        |
| Alb          | F-T4              |
| 2.2 g/dL     | 2.39 μg/dL        |
| T.Bil        | Tumor marker      |
| 0.50 mg/dL   |                   |
| AST          | CEA               |
| 40 IU/L      | 308.1 ng/mL       |
| ALT          | SLX               |
| 34 IU/L      | 320 U/mL          |
| LDH          |                   |
| 738 IU/L     |                   |
| CK           |                   |
| 63 IU/L      |                   |
| Aldolase     |                   |
| 23.7 IU/L    |                   |
| ALP          |                   |
| 255 mU/mL    |                   |
| BUN          |                   |
| 16 mg/dL     |                   |
| Cre          |                   |
| 0.68 mg/dL   |                   |
| Na           |                   |
| 136 mEq/L    |                   |
| K            |                   |
| 5.3 mEq/L    |                   |
| Cl           |                   |
| 101 mEq/L    |                   |

**Discussion**

A spinal MRI of the patient revealed an abnormally high intensity lesion in the C5/6 level cervical cord, with abnormal contrast, and a tumor with abnormal contrast on the left side of the L4/5 level vertebral canal (Fig. 3). The patient was diagnosed with multiple spinal cord and meningeal dissemination ten days after steroid therapy and died due to lung cancer progression five months after the start of nivolumab treatment.
Nivolumab blocks PD-1-mediated signaling and restores antitumor immunity, however, this drug may trigger dermatomyositis as one type of irAE due to compromised immunosuppression, through an excessive immune reaction derived from T cell activation and following an increase in the production of interferon-γ (1, 6, 7).

In this report, the patient’s lung cancer became progressive after nivolumab treatment. It has been reported that dermatomyositis complicates cancer in 9-30% of patients, as a paraneoplastic syndrome (8, 9). Regarding the pathogenesis, it is considered that the antigens that target an immune response are important for evoking a paraneoplastic disorder (10). The skin lesions observed in this case appeared after nivolumab treatment and showed improvement and resolution before steroid therapy, after discontinuing nivolumab, as shown in Fig. 1. Regarding the progressive muscle weakness seen in this case, we hypothesize that the proximal muscle weakness observed in the early phases was myositis-specific, because of MRI and electromyogram abnormalities, while muscle weakness in later phases may have been associated with leg paralysis due to meningeal disseminations. Therefore, we suspect that the occurrence of dermatomyositis in this case was due to nivolumab treatment, rather than a paraneoplastic disorder that accompanied cancer progression. However, this occurrence might have been enhanced by cancer progression in combination with a nivolumab-induced immune reaction, and it has been reported that patients with cancer treated with anti-PD-1 monotherapy occasionally experience hyperprogressive disease such as that observed in this case (11). Recently, several studies have found that cancer-associated myositis in adults is associated with antibodies against transcription intermediary factor-1 gamma and nuclear matrix protein-2, although we did not investigate these antibodies in this case (12). Additional investigations into how dermatomyositis develops in a nivolumab treatment setting are required.

The use of prednisolone is the standard treatment for dermatomyositis, including irAEs incidences (4, 13). However, aggressive treatments, including surgery and/or chemotherapy, for cancer may be the optimal choice for the treatment of cancer-related dermatomyositis, such as paraneoplastic disorder (14). In this case, chemotherapy was not chosen due to the patient’s poor cancer response rate and performance status.

Aldolase concentrations are occasionally elevated in patients with myositis who have normal CK levels, such as in this case, and CK is the most widely used enzyme to diagnose and follow muscle diseases (15). We hypothesize that aldolase measurements could allow for an earlier diagnosis of myositis.

The overall health status results of Checkmate 057 indicate that patients who underwent nivolumab treatment displayed significantly improved symptoms and better qualities of life after treatment (16). Therefore, it is important to consider primary disease progression in the presence of irAEs and perform detailed medical examinations when rare symptoms, such as those pertaining to this case, develop.

Conclusion

We herein reported the first known case of nivolumab-associated dermatomyositis in a patient with lung cancer. It is necessary to consider the progression of the cancer in addition to irAEs when using immune-checkpoint inhibitors, such as nivolumab. We suspect that the frequency of irAEs may increase as the use of immune-checkpoint inhibitors increases for various types of cancer. Therefore, it is crucial to maintain close and constant detailed communication between the treating oncologist and general physician.

The authors state that they have no Conflict of Interest (COI).

References

1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Non-Squamous Non-Small-Cell Lung Cancer. N Engl J Med 373: 1627-1639, 2015.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347, 1975.
3. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer (Oxford, England : 1990) 60: 12-25, 2016.
4. Sheikh Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T lymphocyte antigen 4 blockade. JAMA Dermatol 151: 195-199, 2015.
5. Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol 12: 198-203, 2010.
6. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2: 846-856, 2014.
7. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206: 3015-3029, 2009.
8. Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 84: 68-76, 1976.
9. Sigurjonsdottir B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326: 363-367, 1992.
10. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 4: 36-44, 2004.
11. Champiat S, Derle C, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 23: 1920-1928, 2017.
12. Chinoy H, Fergin N, Oddis CV, Ollier WE, Cooper RG. The diagnostic Utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66: 1345-1349, 2007.
13. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 11: 6-13, 2011.
14. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35: 438-444, 2008.
15. Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am 20: 845-856, 1994.
16. Gralla RJ, Spigel D, Bennett B, et al. PD1.01 (also presented as P
2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel inPts With Advanced Non-Squamous NSCLC From Checkmate 057. J Thorac Oncol 11: S171, 2016.

The Japanese Society of Internal Medicine

Intern Med Advance Publication